Business Type:Trading Company
Product Certification&
Enterprise Certification
Country: China (Mainland)
Business Type:Trading Company
CAS NO.763113-22-0
First class(1-499)KilogramFirst class(500-1000)Kilogram
Our Advantages:
1.We have abundant professional production experience.
2.We have our own chemical factory.
3.Sample is free of charge.
4. Reasonable Price, Excellent Quality & Attentive Service
5. Prompt reply: we can reply your inquiry and email within 24 hours.
6.Fast Delivery: The delivery time is about 10-20 days after receiving the deposit.
7. We have a unity cooperation team
Best price in stock AZD-2281
Product description:
Olaparib (AZD-2281, trade name Lynparza) is an FDA-approved targeted therapy for cancer, developed by KuDOS Pharmaceuticals and later by AstraZeneca. It is a PARP inhibitor, inhibiting poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair. It acts against cancers in people with hereditary BRCA1 or BRCA2 mutations, which include some ovarian, breast, and prostate cancers. In December 2014, olaparib was approved for use as a single agent by the EMA and the FDA. The FDA approval is in for germline BRCA mutated (gBRCAm) advanced ovarian cancer that has received three or more prior lines of chemotherapy.
Company information:
Packing and shipping: